Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2
Drug Approval
Drug Approval | 22 May 2026

Lupin enters China market with approval for Oseltamivir oral suspension

The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment

Drug Approval
Drug Approval | 20 May 2026

Lupin gets tentative FDA nod for Revefenacin inhalation solution

The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)

Drug Approval
Drug Approval | 20 May 2026

Bayer’s stroke drug wins fast-track review in US

The development comes as stroke remains one of the world’s biggest health threats

Drug Approval
Drug Approval | 19 May 2026

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease

Drug Approval
Drug Approval | 19 May 2026

Astrazeneca’s Baxfendy wins US approval as first-in-class hypertension drug

Baxfendy works in a fundamentally different way from current therapies

Drug Approval
Drug Approval | 18 May 2026

Caplin Steriles receives USFDA approval for generic foscarnet sodium injection

Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months

Drug Approval
Drug Approval | 15 May 2026

Lupin receives USFDA nod for Famotidine injection

Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market

Drug Approval
Drug Approval | 15 May 2026

Indoco Remedies' Baddi plant gets EU GMP approval from Malta Medicines Authority

The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026

Drug Approval
Drug Approval | 15 May 2026

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States

Drug Approval
Drug Approval | 14 May 2026

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy

Drug Approval
Drug Approval | 11 May 2026

Bristol Myers Squibb wins EU nod for Sotyktu in active psoriatic arthritis

The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio

Drug Approval
Drug Approval | 07 May 2026

Venus Remedies gets marketing authorization for Ceftriaxone in Argentina

Approval strengthens the company’s growing international anti-infective portfolio

Drug Approval
Drug Approval | 06 May 2026

Caplin Steriles receives USFDA approval for Calcium Gluconate Injection

Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million

Drug Approval
Drug Approval | 05 May 2026

OneSource powers second generic semaglutide nod in Canada

Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs

Drug Approval
Drug Approval | 05 May 2026

Lupin receives USFDA approval for generic Ravicti oral liquid

Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders

Drug Approval
Drug Approval | 04 May 2026

Alkem Laboratories receives 7 observations following US FDA inspection at Daman facility

The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026

Drug Approval
Drug Approval | 04 May 2026

Aurobindo arm CuraTeQ receives Health Canada approval for bevacizumab biosimilar Bevqolva

Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market

Drug Approval
Drug Approval | 01 May 2026

Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection

Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada

Startup

Digitization